In the randomized controlled trial involving early ADPKD, 558 hypertensive individuals aged 15–49 with ADPKD and an eGFR of at least 60 mL/min/1.73 m2, participants were randomly allocated to receive either a standard blood pressure target (120/70 to 130/80 mm Hg) or a lower blood pressure target (95/60 to 110/75 mm Hg), along with either an angiotensin-converting-enzyme inhibitor (lisinopril) combined with an angiotensin-receptor blocker (telmisartan) or lisinopril combined with a placebo. The gene discussed is ACE; the disease is autosomal dominant polycystic kidney disease.